Abpro Holdings (ABP) Q2 2026 earnings summary

Executive summary

• Focused on next-generation antibody therapeutics in immuno-oncology, ophthalmology, and infectious disease, with lead candidates ABP-102 and ABP-201 in early-stage development.

• Securities delisted from Nasdaq in February 2026, now trading on OTC Pink Limited Market, impacting liquidity and capital-raising ability.

• Significant cost reductions implemented, including R&D personnel furloughs and terminations in late 2025.

Financial highlights

• No revenue generated for the three or six months ended June 30, 2026 or 2025.

• Net loss for Q2 2026 was $0.9M, a 68% improvement from $3.0M in Q2 2025; six-month net loss was $2.0M, a 71% improvement from $6.9M in 2025.

• Operating expenses for Q2 2026 were $1.2M, down 48% year-over-year; six-month operating expenses were $2.1M, down 60%.

• Cash as of June 30, 2026 was $4.2M.

Outlook and guidance

• Management concluded there is substantial doubt about the ability to continue as a going concern within one year due to insufficient cash to cover liabilities.

• Plans to seek additional funding through equity, debt, collaborations, and grants; may need to further reduce operations if funding is not secured.